Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.

Antineoplastic Agents / therapeutic use Histone Deacetylase Inhibitors / pharmacology Histone Demethylases / antagonists & inhibitors Humans Male Pargyline / pharmacology Prostatic Neoplasms / drug therapy

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
23 12 2021
Historique:
pubmed: 16 12 2021
medline: 22 1 2022
entrez: 15 12 2021
Statut: ppublish

Résumé

Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer agents. Resultantly, compound

Identifiants

DOI: 10.1021/acs.jmedchem.1c00966 PMID: 34908406
pubmed: 34908406
doi: 10.1021/acs.jmedchem.1c00966
doi:

Substances chimiques

Antineoplastic Agents 0
Histone Deacetylase Inhibitors 0
Pargyline 9MV14S8G3E
Histone Demethylases EC 1.14.11.-
KDM1A protein, human EC 1.5.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17824-17845

Auteurs

Ritu Ojha (R)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.

I-Chung Chen (IC)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.

Chien-Ming Hsieh (CM)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
TMU Research Center of Drug Discovery, Taipei Medical University, Taipei 110031, Taiwan.

Kunal Nepali (K)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
TMU Research Center of Drug Discovery, Taipei Medical University, Taipei 110031, Taiwan.

Row-Wen Lai (RW)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.

Kai-Cheng Hsu (KC)

Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110031, Taiwan.
TMU Research Center of Drug Discovery, Taipei Medical University, Taipei 110031, Taiwan.
Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
ORCID: 0000-0002-9022-6673

Tony Eight Lin (TE)

Master Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110031, Taiwan.

Shiow-Lin Pan (SL)

Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110031, Taiwan.
TMU Research Center of Drug Discovery, Taipei Medical University, Taipei 110031, Taiwan.
Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.

Mei-Chuan Chen (MC)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
TMU Research Center of Drug Discovery, Taipei Medical University, Taipei 110031, Taiwan.
Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei 110031, Taiwan.
Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.

Jing-Ping Liou (JP)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
TMU Research Center of Drug Discovery, Taipei Medical University, Taipei 110031, Taiwan.
ORCID: 0000-0002-3775-6405

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Installation of Pargyline, a LSD1 Inhibitor,...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de désacétylase d'histone › Installation of Pargyline, a LSD1 Inhibitor,...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxidoreductases acting on CH-NH group donors › Oxidoreductases, (N-demethylating) › Histone Demethylases › Installation of Pargyline, a LSD1 Inhibitor,...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Installation of Pargyline, a LSD1 Inhibitor,...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Composés benzyliques › Benzylamines › Pargyline › Installation of Pargyline, a LSD1 Inhibitor,...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Installation of Pargyline, a LSD1 Inhibitor,...